In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, RegenXBio, and Rocket Pharmaceuticals. According to TipRanks, Foroohar has an average return of -8.0% and a 42.58% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Moderna with a $42.71 average price target, representing a 51.45% upside. In a report released today, Bank of America Securities also reiterated a Sell rating on the stock with a $24.00 price target.
Based on Moderna’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $143 million and a GAAP net loss of $825 million. In comparison, last year the company earned a revenue of $221 million and had a GAAP net loss of $1.28 billion
Read More on MRNA: